ArticleFrontiers in veterinary science2025
A novel cross-validated machine learning based Alertix-Cancer Risk Index for early detection of canine malignancies.
Article in Frontiers in veterinary science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Artificial intelligence and laboratory biomarkers in veterinary medicine: an update about machine learning applications.The veterinary quarterly · 2026Review
- Machine learning-assisted detection of canine mammary tumors using serum autoantibody signatures.The veterinary quarterly · 2026Article
- Generative AI in Veterinary Pathology: Feasibility of a GPT-Based Assistive Tool for Gross, Cytologic, and Histopathologic Assessment of Canine Cutaneous Neoplasms-A Pilot Study.Animals : an open access journal from MDPI · 2026Article
- A machine learning model for cancer screening in dogs using comprehensive circulating microRNA profiles.Journal of veterinary internal medicine · 2026Article
- The application of artificial intelligence in veterinary oncology: a scoping review.BMC veterinary research · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: The demand for non-invasive tumor biomarkers in veterinary field has recently grown significantly. Thymidine kinase 1 (TK1) is one of the non-invasive proliferation biomarkers that has been used for diagnosis and treatment monitoring of different canine malignancies. However, recent studies showed that the combination of TK1 with inflammatory biomarkers such as canine C-reactive protein (cCRP) can enhance the sensitivity for early tumor detection. Herein, we developed a machine learning (ML) model, i.e., Alertix-Cancer Risk Index (Alertix-CRI) which incorporates canine TK1 protein, CRP levels in conjunction with an age factor. Methods: A total of 287 serum samples were included in this study, consisting of 67 healthy dogs and dogs with different tumors (i.e., T-cell lymphoma Results: Both the TK1-ELISA and cCRP levels were significantly higher in the tumor group compared to healthy controls ( Conclusion: These results demonstrate that the novel Alertix-CRI could be used as a decision-support tool helping clinicians to early differentiate dogs with malignant diseases from healthy. Additionally, these findings would facilitate the advancement of more precise and dependable diagnostic tools for early cancer detection and therapy monitoring within the realm of veterinary medicine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.